Pluristem Therapeutics, Inc. (PSTI) Secures $8 Million EU Grant for Critical Limb Ischemia Study
Pluristem Therapeutics, Inc. (NASDAQ: PSTI), a leading Israel-based developer of placenta cell therapies for various ailments including ischemia, inflammation, radiation damage and hematology disorders, recently secured an $8 million grant from the European Union for its critical limb ischemia (CLI) program, according to a news release (http://nnw.fm/YvNo5) issued August 9. The CLI grant, offered under the EU’s largest research and innovation program, Horizon 2020, will cover a significant portion of Pluristem’s PLacental eXpanded (PLX) PAD cells study, which will enroll about 250 U.S. and European patients suffering from CLI Rutherford Category 5. This category of patients is commonly unsuitable for…